ArticleInternational journal of general medicine2026
Laboratory Biomarker Profiles and Phenotypic Discrimination in Coronary Artery Disease with Metabolic and Renal Comorbidities: A Cross-Sectional Study.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Coronary artery disease (CAD) frequently coexists with metabolic and renal comorbidities, including type 2 diabetes mellitus (T2DM), hyperuricemia (HUA), and chronic kidney disease (CKD), which may influence laboratory biomarker profiles. This study aimed to characterize haematological, biochemical, and urinary parameters across CAD phenotypes and identify laboratory predictors associated with these comorbidity patterns. Methods: A retrospective cross-sectional study was conducted at Guangzhou Liwan Central Hospital between January 1 and December 31, 2024, including 544 adult patients with CAD. Diagnoses of CAD, T2DM, HUA, and CKD were defined according to established clinical criteria documented in hospital electronic medical records. Patients were stratified into seven phenotypic subgroups based on the presence of T2DM, HUA, and CKD. Demographic characteristics and laboratory parameters-including haematological indices, biochemical markers, and urinary findings-were extracted from electronic records. Between-group comparisons were performed using ANOVA and chi-square tests, and multivariable logistic regression was used to identify laboratory predictors associated with CAD comorbidity phenotypes. Results: Significant differences in demographic and laboratory parameters were observed across CAD phenotypes. Gender distribution differed significantly between groups (p = 0.004). The CAD+HUA group had the highest mean age (84.7 ± 10.1 years), whereas the CAD+T2DM+CKD group had the lowest (76.4 ± 11.0 years; p = 1.77 × 10 Conclusion: Haematological, biochemical, and urinary biomarkers differ across CAD phenotypes with metabolic and renal comorbidities. These laboratory indicators show moderate discriminatory potential for identifying CAD comorbidity patterns, although further validation in larger prospective cohorts is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.